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The immune response to influenza A virus is charac-
terized by an influx of both macrophages and T lym-
phocytes into the lungs of the infected host, accom-
panied by induced expression of a number of CC
chemokines. CC chemokine receptors CCR5 and
CCR2 are both expressed on activated macrophages
and T cells. We examined how the absence of these
chemokine receptors would affect pulmonary chemo-
kine expression and induced leukocyte recruitment
by infecting CCR5-deficient mice and CCR2-deficient
mice with a mouse-adapted strain of influenza A virus.
CCR5/ mice displayed increased mortality rates as-
sociated with acute, severe pneumonitis, whereas
CCR2/ mice were protected from the early patho-
logical manifestations of influenza because of defec-
tive macrophage recruitment. This delay in macro-
phage accumulation in CCR2/ mice caused a
subsequent delay in T cell migration, which corre-
lated with high pulmonary viral titers at early time
points. Infected CCR5/ mice and CCR2/ mice
both exhibited increased expression of the gene for
MCP-1, the major ligand for CCR2/ and a key reg-
ulator of induced macrophage migration. These stud-
ies illustrate the very different roles that CCR5 and
CCR2 play in the macrophage response to influenza
infection and demonstrate how defects in macro-
phage recruitment affect the normal development of
the cell-mediated immune response. (Am J Pathol
2000, 156:1951–1959)
Chemoattractant cytokines, or chemokines, are small,
inducible, pro-inflammatory molecules involved in the re-
cruitment of leukocytes to sites of injury or infection. More
recently, research has highlighted the role of chemokines
in the regulation of certain aspects of hematopoiesis1 and
the normal trafficking of residential leukocytes to both
lymphoid and nonlymphoid organs.2,3 The biological
effects of chemokines are mediated through their inter-
action with members of a large group of seven transmem-
brane-spanning (serpentine), G-protein-coupled recep-
tors.4 Although virtually every tissue in the body can
produce chemokines, chemokine receptor expression is
generally limited to activated leukocyte populations. CXC
chemokine receptors were initially identified on neutro-
phils, and have thus been traditionally associated with
acute inflammation. In contrast, CC chemokine receptors
are expressed on a wide variety of cells, including eosin-
ophils, basophils, monocytes, macrophages, and T lym-
phocytes.5,6 Therefore, it is not surprising that CC che-
mokines have been implicated in a number of more
chronic diseases including atherosclerosis,7–9 arthritis,10
glomerulonephritis,11 and allograft rejection.12
The influx of mononuclear inflammatory cells into in-
fected host tissues has long been recognized as the
hallmark of the host defense mechanism against viral
infection.13,14 This cell-mediated immunity is the predom-
inant mechanism for containment and recovery from pri-
mary viral infections. Consequently, patients who are im-
munocompromised, including those who are elderly or
HIV-infected, are more susceptible to the extreme mani-
festations of viral infection.15 In general, the pathogene-
sis of lytic viral infections, such as influenza infections,
can be divided into two phases, the cellular events that
precede T cell invasion and those that follow it. The initial
attack of influenza A on respiratory epithelial cells causes
the extravasation of small numbers of blood-derived neu-
trophils, followed by larger numbers of blood monocytes/
macrophages into the infected lung. During this period,
viral replication continues in the epithelial cells and infec-
tion spreads to the collecting macrophages.16–18 These
processes alone are not able to clear the virus from the
lung. By day 7, CD8 cytotoxic T cells (CTLs) from
nearby mediastinal lymph nodes (MLNs) begin to accu-
mulate in the infected lungs and the efficient process of
T-cell mediated viral clearance begins.15,16,19 Although
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this cell-mediated mechanism is required for host protec-
tion and recovery, the overwhelming inflammatory cell
accumulation can be harmful to the infected host by
aggravating clinical symptoms and contributing to poten-
tially lethal lung pathology.20,21 Although it is still unclear
as to which inflammatory proteins mediate influenza A-
induced leukocyte recruitment, virologists have recently
begun to focus on the potential role of chemokines in this
process.14,22
A number of in vitro studies have associated influenza
A infection with increased monocyte and epithelial cell
expression of several CC chemokines, including RAN-
TES,17,23,24 MIP-1, and MCP-1,17,24,25 and the CXC
chemokine, IP-10.25 Additionally, MIP-1-deficient mice
infected with the influenza A virus displayed a marked
reduction in virus-induced pneumonitis, but a significant
increase in viral titers at days 6 and 7 postinfection.22
This work implicated MIP-1 as a major T cell chemoat-
tractant functioning in the lungs of influenza-infected
mice. Although it is known that macrophages are respon-
sible for the production of inflammatory mediators (in-
cluding MIP-1) that regulate the T cell response to in-
fluenza A virus infection,26 it is not known which, if any,
chemokines promote the early activation and migration of
these macrophages to infected lungs.
In recent years insight into the pathogenesis of influ-
enza A has been gained through the use of murine trans-
genic and gene knockout animal models.21,22,27–31 In this
report, we have explored the roles of two chemokine
receptors, CCR5 and CCR2, in influenza A-induced pul-
monary macrophage recruitment. CCR2-deficient mice,
in particular, as well as MCP-1-deficient mice have been
previously reported to have significant defects in macro-
phage recruitment.32–35 In these studies, we infected
mice deficient in either CCR5, a receptor for MIP-1,
MIP-1, and RANTES, or CCR2, the primary receptor for
MCP-1, with a mouse-adapted influenza A virus (PR/8/
34). We examined the pathological manifestations of the
virus as well as events occurring simultaneously in the
regional lymph nodes. We found that CCR5 deficiency
leads to a hyperacute inflammatory response that is often
fatal, whereas CCR2 deficiency leads to a milder inflam-




CCR2/, MIP-1/, and / control mice were gen-
erated and maintained as previously described22,32 and
were on mixed 129/Ola X C57BL/6J genetic background.
Wild-type control mice carry the CCR gene cluster de-
rived from the 129/Ola strain. CCR2/ mice were bred
with MIP-1/ mice to obtain mice that were heterozy-
gous for both mutations (CCR2//MIP-1/). The dou-
ble heterozygotes were then intercrossed to generate
mice which were doubly deficient (CCR2//MIP-1/).
CCR2 and MIP-1 genotypes were determined by meth-
ods that have been described previously.21,32 CCR5/
mice were generated by targeted replacement of the entire
CCR5 coding region with a neomycin-resistance gene in
embryonic stem cells. Correctly targeted embryonic stem
cells were selected andmale chimeras were generated and
mated to C57BL/6J females. F1 heterozygotes were mated
to obtain homozygous CCR5/ mice (WA Kuziel, TC Daw-
son, RL Reddick, and N Maeda, manuscript in preparation).
All experimental mice were bred and maintained in patho-
gen-free conditions until viral inoculation. All animal exper-
iments were done in accordance with National Institutes of
Health guidelines and protocols approved by the Animal
Care and Use Committee at the University of North Carolina
at Chapel Hill.
Virus Infection and Quantitation
Influenza A/Puerto Rico/8/34 (A/PR/8/34) virus grown in
the allantoic cavity of 10-day-old embryonated hen eggs
was a gift from Dr. John F. Sheridan, Ohio State Univer-
sity. At 6 to 10 weeks of age, mice were anesthetized with
a ketamine-xylazine solution, and intranasally infected
with 5 hemeagglutinating units (HAU) of the influenza
A/PR/8/34 stock. Virus was isolated from the lungs of
infected mice 5 days postinfection by first weighing, then
grinding the tissue into minimal essential medium, fol-
lowed by a series of freeze/thaw cycles and high-speed
centrifugation of the ground tissue. The supernatant was
collected and 10-fold serial dilutions of 0.1-ml aliquots
were added in replicates of six to 96-well plates of con-
fluent Madin Darby canine kidney cells. Plates were in-
cubated for 24 hours at 37°C. Viral titers (expressed as
TCID50) were determined as previously described.
36 In-
dividual group titers were compared to the control titers
with unpaired Student’s t-tests.
Histological Analysis of the Lungs
At days 2, 3, 5, 16, and 25 postinfection, animals were
sacrificed and one lung was resected, inflated, and em-
bedded in freezing embedding medium (Tissue-Tek, Tor-
rance, CA), then snap-frozen in isopentane cooled with
liquid nitrogen. Frozen serial sections from all animals
were stained with hematoxylin and eosin (H&E) and ex-
amined microscopically. Each specimen was assigned a
score of 0 to 4 based on the severity of lung patholo-
gy.22 Additional cryosections selected for immunohisto-
chemical study were acetone-fixed and incubated with
an antibody against one of several mouse leukocyte
markers. Sections were incubated with a series of perox-
idase-labeled secondary antibodies, developed with
9-amino-3-ethylene-carbazole, and counterstained with
Mayer’s hematoxylin (Sigma Diagnostics, St. Louis, MO).
Primary antibodies that were used included: a mouse
macrophage/monocyte marker, MOMA-2 (Serotec, Ox-
ford, UK); a mouse neutrophil marker, NIMPR40 (kindly
received from Dr. Peter Heeringa, University of North
Carolina, Chapel Hill); and lymphocyte markers CD8a,
CD4, and CD3e (Pharmingen, San Diego, CA).
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RNase Protection Assay
Total RNA from lungs and MLNs of uninfected mice (day
0) and infected mice at days 2 and 3 postinfection was
prepared using TRIzol Reagent (Life Technologies, Inc.,
Grand Island, NY). Chemokine mRNA levels were deter-
mined using the RiboQuant Multipurpose Ribonuclease
Protection Assay (RPA) System with the mCK-5 probe set
(Pharmingen, San Diego, CA). The dried gel was ex-
posed to X-ray film and developed for 24 hours at 70°C.
Bands were detected and densitometrically quantitated
using RiboQuant software. All chemokine values were
normalized to the housekeeping gene Gapdh. Each data
point represents a sample of pooled RNA from two indi-
vidual animals. Group values were compared indepen-
dently to control values using unpaired Student’s t-tests.
Flow Cytometry and Cytospin Preparations
Cell suspensions from the MLNs and bronchoalveolar
lavage (BAL) fluid of infected mice were obtained 5 days
postinfection and pooled by genotype. Cells were
stained with the following anti-mouse mAbs: PE anti-CD3,
FITC anti-CD4, or FITC anti-CD8 (Pharmingen, San Di-
ego, CA). After staining, cells were sorted and counted
by FACS analysis on a FACScan machine using LYSYS II,
Version 1.1 software (Becton Dickinson, San Jose, CA).
Pooled BAL cells which were not used for FACS analysis
were spun for 7 minutes at 1,000 rpm onto serum-coated
slides using a cytocentrifuge (StatSpin; Shandon Scien-
tific, Runcorn, UK). After Giemsa-Wright staining, leuko-
cyte differentials were determined by averaging three
counts of at least 250 cells each.
Results
Survival Rates and Influenza A Viral Clearance in
CCR5/ and CCR2/ Mice
To asses the impact of CCR5 and CCR2 on susceptibility
to influenza A virus infection, age-matched control (/),
CCR5/, CCR2/, and CCR2//MIP-1/ (doubly-
deficient) mice were inoculated intranasally with 5 HAU of
mouse-adapted influenza A/PR/8/34. As shown in Figure
1A, at this dose, 30% of control mice succumbed to the
virus by day 10 postinfection. However, CCR5 deficiency
resulted in a sharp increase in mortality early in the
course of infection; 42% of all CCR5/ mice died by day
6. CCR5/ mice that survived this early death recovered
and lived well beyond day 16 postinfection. In striking
contrast to these results, CCR2-deficient mice were sub-
stantially less susceptible to death from influenza A in-
fection. As a group, these animals exhibited only 10%
mortality through day 16 postinfection. A strain of mice
deficient in both CCR2 and MIP-1 was the most pro-
tected, exhibiting no mortality during the observation pe-
riod for this experiment. Because all of the animals used
are hybrids between 129/Ola and C57BL/6 strains, we
cannot rule out completely a possibility that nonselected
alleles have been sorted differently in each group. How-
ever, considering that the loci unlinked to CCR5-CCR2
are equally randomized and that the wild-type controls
carry CCR5-CCR2 loci from 129/Ola strain, it is unlikely
that the random sorting of alleles can account for the
dramatic differences in pneumonitis observed in these
groups of animals.
To determine whether these differences in influenza
virus susceptibility correlated with T-cell-mediated viral
clearance, we measured lung viral titers at day 5 postin-
fection (Figure 1B). Although some of the CCR5/ mice
died prematurely, there was no significant difference in
the viral load harbored by the surviving CCR5/ mice
when compared to the control mice. In contrast, CCR2-
deficient animals, which exhibited an increased survival
rate, had 10- to 100-fold higher viral titers than the /
controls. Previous results obtained by Cook et al,22
showed that deletion of the MIP-1 gene leads to a
similar increase in viral titers after influenza virus infec-
tion. Our data using the CCR2//MIP-1/ double-
knockout mice confirm this phenotype and seem to indi-
cate that the additional deletion of CCR2 exacerbates this
effect by causing even higher viral titers at this time point.
These results suggest that the absence of both CCR2
and MIP-1 may independently cause delays in the mi-
gration of key leukocyte populations after influenza infec-
Figure 1. The effect of CCR5 and CCR2 deletion on influenza associated
mortality and viral titers. A: Mortality of / (f), CCR5/ (F), CCR2/
(Œ), or CCR2//MIP-1/ ( mice (n  19 per group) infected intrana-
sally with 5 HAU of influenza A (strain A/PR/8/34) and monitored for 16
days. Data represent two independent experiments combined. B: Influenza A
titers in /, CCR5/, CCR2/, and CCR2//MIP-1/ mice measured
at day 5 after infection with 10 HAU of virus. Data are expressed as log
[TCID50] per gram of tissue. *P  0.01 versus / group by Student’s t-test.
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tion, which may subsequently cause a delay in viral clear-
ance. In addition, our results along with those from Cook
et al,22 show that influenza-induced mortality does not
directly correlate with increases in virus replication.
Altered Severity of Pulmonary Pathology in the
Absence of CCR2 and CCR5
The above results confirm that the sometimes fatal, down-
stream pathological events that occur after influenza in-
fection are clearly not because of an overwhelming viral
burden in the lungs. This implies that the harsh pulmo-
nary pathology may be caused by the responding inflam-
matory cells rather than by the cytopathic effects of the
virus itself. Indeed, the early increase in mortality seen in
the surviving CCR5/ mice was associated with unusu-
ally massive leukocyte accumulations and severe pulmo-
nary tissue damage as early as day 2 postinfection (Fig-
ure 2C), compared to relatively mild inflammation in the
control animals (Figure 2A). Likewise, the protective ef-
fect of the CCR2 deficiency as seen in the survival study
was confirmed by histological examination of the intact
lungs from infected mice. At days 3 and 5 postinfection,
CCR2/ mice had a marked reduction in pulmonary
inflammatory cell infiltration (Figure 3, E and F), com-
pared to control mice (Figure 3, A and B). Additionally,
the thickening of the septal walls, disarray/disorganiza-
tion of the bronchial epithelial cells, and the areas of
consolidation that were present in control lungs at day 5
postinfection (Figure 3B) were noticeably absent in
CCR2/ mice at day 5 postinfection (Figure 3F). How-
ever, an extended time course revealed that CCR2/
animals eventually developed some of these histopatho-
logical characteristics. When histological sections from
all groups for five time points were scored 0 to 4 based
on the amount of inflammation and the severity of tissue
damage, the histological scores of some of the CCR2/
mice at day 16 were as high as those of CCR5/ mice at
day 2 (Figure 4). However, no deaths occurred in the
CCR2/ animals, suggesting that cell populations in-
volved may be different in these two groups of mice
although the histological scores look similar. All surviving
animals were able to recover from the infection by day 25
postinfection. These results indicate that CCR5 defi-
ciency accelerates the onset of the pathological manifes-
tations of influenza A virus, whereas CCR2 deficiency
causes a delay in the onset of the normal pathological
manifestations of influenza A virus.
Defective Macrophage Function in Infected
CCR5/ and CCR2/ Mice
To determine which leukocyte subpopulation was prema-
turely responding to the influenza A virus infection in
CCR5/ mice, immunohistochemical analysis was per-
formed. As expected at day 2 postinfection, both control
mice and CCR2/ mice had NIP/R40-positive neutro-
phils present in the lungs (data not shown). However,
macrophages were the predominant cell type infiltrating
at day 2 postinfection in CCR5/ lungs, as illustrated by
an intense positive MOMA-2 staining (Figure 2D) com-
pared to light staining in the control lungs (Figure 2B).
Neither CD4 T cells, nor CD8 T cells were present at
day 2 postinfection in either the /, CCR2/, or
CCR5/ mice (data not shown).
We and others have previously reported that mice
deficient in either MCP-1 or CCR2 have pronounced de-
fects in macrophage function when immunologically
challenged.32–35 This also proved to be true of CCR2/
mice when challenged with the influenza A virus. Al-
though the acute neutrophilic response was unaltered in
the CCR2 knockout mice, these mice failed to mount the
expected mononuclear attack that begins with infiltration
of macrophages by day 3 postinfection in control mice. In
fact, even at day 5 postinfection, the few identifiable
leukocytes that were present in CCR2/ lungs were still
neutrophils (Figure 3G). This was confirmed by a cyto-
logical preparation of bronchoalveolar lavage (BAL) cells
5 days postinfection, which clearly shows that polymor-
phonuclear leukocytes (neutrophils) continue to be the
dominating cell type at this time point in CCR2-deficient
mice (Figure 3H). When the BAL differentials were
counted, only 10  0.7% of the BAL cells in CCR2/
mice were monocytes/macrophages, compared with
60  1.5% in control mice at the same time point (Figure
Figure 2. Inflammatory response to influenza A in lungs of control and
CCR5-deficient mice. All histology sections are from lung tissues taken at day
2 postinfection with 5 HAU of influenza A; original magnification, 100. A
and B: Sections from / lungs show H&E staining of only a few inflam-
matory cells characteristic for this early time point (A) and MOMA-2 staining
of a few, sparse resident alveolar macrophages (B). C and D: Sections from
CCR5/ lungs show H&E staining of massive inflammatory cell infiltration
and interstitial pneumonitis (C) and intense MOMA-2 staining of the infiltrat-
ing macrophages (D).
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5). These experiments illustrate that the delay in the
pathogenesis of influenza in the CCR2/ mice is caused
by their inability to properly recruit macrophages during
an inflammatory attack.
MCP-1 Modulation of the Macrophage
Response to Influenza A Virus
Although the defective macrophage recruitment in
CCR2/ mice was not surprising, the hyperacute mac-
rophage accumulation in the CCR5/ animals was un-
expected. To investigate the mechanism of this aberrant
response, we examined pulmonary chemokine expres-
sion levels of several relevant CC chemokine genes after
influenza virus infection. Image densitometry of an RNase
protection assay revealed a threefold increase in RAN-
TES RNA expression at day 2 postinfection in CCR5/
mice compared to control animals or CCR2-deficient
mice (Figure 6A). Excess RANTES might attract addi-
tional macrophages through binding to its alternate re-
ceptor, CCR1, on these cells. IP-10 expression was in-
creased in all animals with slightly more increase in the
Figure 3. Inflammatory response to influenza A in lungs of control and CCR2-deficient mice. All histology sections are from lung tissue taken at days 3 and 5
postinfection with 5 HAU of influenza A; original magnification, 100. Cytological preparations are BAL samples taken at day 5 postinfection; original
magnification, 400. A–C: Sections from / lungs show H&E staining of the acute inflammatory cell infiltrate typically seen 3 days postinfection (A), the areas
of chronic inflammation and tissue consolidation, thickening of the septal walls, and disorganization of the bronchial epithelial cells typically seen 5 days
postinfection (B), and NIMPR40 staining of the relatively few neutrophils seen at this time point in / mice (C). D: Giemsa-Wright staining of the BAL cells
obtained from the / mice 5 days postinfection. E–G: Sections from CCR2/ lungs show H&E staining of less cellular infiltration 3 days postinfection (E),
absence of the epithelial cell damage and consolidating pneumonitis that is seen in control mice at day 5 postinfection (F), and relatively intense NIMPR40 staining
of the accumulating neutrophils, which is the dominant leukocyte population present in CCR2/ lungs 5 days postinfection (G) . H: Giemsa-Wright staining of
CCR2/ BAL cells obtained at day 5 postinfection.
Figure 4. Time course of pulmonary pathology scores for surviving /,
CCR5/, and CCR2/ mice after influenza virus infection. All lung histol-
ogy sections were scored (blinded) 0 to 4 based on the severity of
inflammation and tissue damage. For this experiment, CCR5/ mice were
not analyzed at day 5 postinfection. Each data point represents the average
of 3 to 5 mice per group for each time point. *, P  0.002 versus / group,
and †, P  0.05 versus / group both by Student’s t-test.
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CCR5/ mice, which could also be contributing to the
macrophage response by their binding to other, intact
receptors. More likely, however, the excess macrophage
accumulation in CCR5/ mice results from increased
expression of MCP-1, a key regulator of induced macro-
phage migration. Both the CCR5/ and CCR2/ ani-
mals exhibited a twofold increase in day 2 postinfection
pulmonary MCP-1 RNA levels relative to the levels in
control mice (Figure 6A). As would be expected, the
overexpression of MCP-1 correlates with an increased
migration of macrophages in CCR5/ mice, but not in
mice lacking CCR2, the major receptor for MCP-1. There
were no significant differences in eotaxin, MIP-1, MIP-
1, MIP-2, or TCA-3 levels in the CCR2/ or CCR5/
mice when compared to controls.
Delayed T Cell Response in CCR2/ Mice
The cellularity of MLNs of mice infected with influenza A
virus increases rapidly, with maximal total cell counts
reached by day 5 postinfection. All major lymphocyte
subsets are involved in this expansion, including CD4
and CD8 T cells.37 At day 5 postinfection, 23% of total
MLN cells in control mice were CD8 (consistent with
previous reports). These numbers were modestly re-
duced in the MLNs of CCR2/ mice to 19% CD8 T
cells (Table 1). Additionally, the percentage of total
(CD3) T cells was substantially reduced in the CCR2/
MLNs (37% versus 53% in /). As shown in Figure 6B,
this decrease in T cell numbers in MLNs of CCR2/
mice correlates with a decrease in MLN expression of
RANTES. These data imply that, relative to control MLNs,
MLNs of CCR2/ mice are less activated, and that fewer
CTLs are homing to or dividing in the MLNs of these
animals. Subsequently, there will be fewer primed CD8
T cells to localize to the site of virus growth. In fact, FACS
analysis did reveal a marked reduction in the percentage
of CD8 T cells in the BAL fluid of CCR2/ mice com-
pared to controls (data not shown). This complements the
results of immunohistochemical analyses that indicated
an absence of CD3 or CD8 T cells in the intact lungs
of CCR2/ mice at day 5 postinfection (data not shown).
Altogether, these experiments demonstrate that proper
signaling through CCR2 is necessary for lymphocyte ac-
cumulation in secondary lymphoid organs and for the
subsequent trafficking to influenza infected tissues.
Discussion
Infection of CCR5- and CCR2-deficient mice with influ-
enza A virus has yielded several unexpected and striking
results regarding influenza-induced immunity and the as-
sociated pathology. First, CCR5/ mice show an accel-
erated macrophage accumulation in the lungs and in-
creased mortality. Second, the acute inflammation seen
in CCR5/ mice is opposite from the protective effects
that is seen in mice deficient in the CCR5 ligand, MIP-1.
Figure 5. Differential leukocyte counts of BAL cells obtained from influenza-
infected / and CCR2/ mice. Data represents the average of 3 counts (of
approximately 300 cells per count) from one pooled sample per group (each
group  5 mice pooled).
Figure 6. Time course of chemokine mRNA expression levels in the lung (A)
and the MLN (B). RNA was obtained from uninfected (day 0) tissues and
from postinfection (day 2, day 3) tissues of /, CCR5/, and CCR2/
mice. RNA was prepared and chemokine mRNA was detected by a multi-
probe RNase protection assay and quantified by image densitometry, as
described in Materials and Methods. Each data point represents a sample of
pooled RNA from two individual animals and chemokine mRNA amounts
were expressed relative to that of GAPDH.




Percent cells staining for
CD8 CD4 CD3
/* 23 30 53
CCR2/* 19 17 37
*Group values represent the average of two samples with four
pooled MLN per sample.
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Third, the virus-infected CCR2/ mice have increased
survival rates compared to controls, in the presence of an
early block in pulmonary macrophage accumulation and
an increased viral load. All of these results highlight the
importance of macrophages in generating an appropri-
ate immune response to influenza infection and in the
development of associated lung pathology. Macro-
phages may both directly and indirectly contribute to
influenza associated lung pathology. A direct contribu-
tion of macrophages to influenza-induced lung pathology
is illustrated by their ability to express inducible nitric-
oxide synthase (NOS2) after becoming infected.38 This
causes macrophage secretion of potentially injurious in-
ducible nitric-oxide synthase-derived nitric oxide metab-
olites. Deletion of the inducible nitric-oxide synthase
gene confers protection against influenza-induced lethal
lung pathology, without altering CTL activity.28 Macro-
phages can also indirectly control the progression of
influenza pathogenesis by regulating T cell response.
Just before the induction of apoptotic cell death,17,39
infected macrophages secrete cytokines such as TNF,
IL-1, IL-6, and M-CSF, and chemokines such as MIP-1,
RANTES, and IP-10 all of which could potentially contrib-
ute to lung pathology by inducing the activation and
migration of CTLs to the site of an influenza infec-
tion.17,21,26,40–42 Thus, the macrophage response to the
influenza virus leads to the rapid onset of a proinflamma-
tory signaling cascade and enhanced activation and im-
migration of lymphocytes into the lung. Once present in
the lung, these lymphocytes, specifically CTLs, can rec-
ognize and directly lyse virally infected cells, thereby
eliminating the virus and initiating recovery of the tis-
sue.43
Inflammation in response to primary influenza virus
infection not only involves macrophages and CTLs, but
also involves chemokine-dependent trafficking of den-
dritic cells and natural killer cells in-between the site of
infection, the circulation, and the draining lymph nodes.
CC chemokine receptors CCR5 and CCR2 are ex-
pressed on all of these cell types,41,44 and several recent
reports describe the production of various CCR5 and
CCR2 ligands by mononuclear and epithelial cells after
being infected by influenza A virus.17,23,24,45 Thus, CCR5
and/or CCR2 could potentially modulate both the afferent
and efferent phases of the immune response to influenza
virus infection.
In our studies, we show that CCR5 is not absolutely
required for macrophage recruitment into influenza-in-
fected lungs or for control of viral replication. CCR5 de-
ficiency does, however, lead to a more negative clinical
outcome relative to controls, with approximately half of all
influenza-infected CCR5-deficient mice dying prema-
turely as a result of early, overwhelming macrophage
accumulation in the lungs. Although not proven in our
experiments, this accelerated macrophage accumulation
is likely to be linked to enhanced expression of MCP-1
and RANTES (Figure 6A), and possibly of IP-10, and their
binding to other intact chemokine receptors on the
CCR5-deficient macrophages. In other experiments, we
have also observed enhanced inflammatory cell recruit-
ment in the lungs of CCR5/ mice after primary infection
with Cryptococcus neoformans.46 The relationship be-
tween the absence of CCR5 signaling and increased
chemokine expression is not clear at this time, but alter-
ations in leukocyte development or trafficking patterns
directly related to CCR5 deficiency may be involved.
The enhanced lung inflammation and pathology of
CCR5/ mice stands in sharp contrast to the reduced
inflammation and pathology observed in mice deficient in
MIP-1, a CCR5 ligand.22 These results together suggest
that during influenza infections, MIP-1 primarily func-
tions through another of its known receptors (CCR1,
CCR4), and that its interactions with CCR5 have limited, if
any, importance for the pulmonary mononuclear re-
sponse to influenza virus infection. These observations
underscore the complexity of the chemokine system and
the difficulty of relating the interplay of chemokines and
their receptors in vitro, with leukocyte function and bio-
logical consequences in vivo.
It has been well established that the loss of functional
CCR2 does not alter blood monocyte levels, but severely
impairs the ability of blood monocytes/macrophages to
respond to certain types of injurious stimuli or specific
pathogenic agents.7,32–34 Our studies implicate influenza
A virus as yet another such pathogen whereby mononu-
clear leukocyte activation and migration is mediated by a
CCR2/MCP-1-dependent mechanism. Despite increased
levels of MCP-1 RNA in the lungs of infected CCR2/
mice, there is substantially reduced pulmonary macro-
phage accumulation in these animals. This correlates
with reduced mortality even though the viral titers were
10- to 100-fold higher than in control or CCR5/ mice at
an early time point. These results suggest that the patho-
logical manifestations of influenza infections are caused
by the massive accumulation of inflammatory cells and
not by the intrinsic cytopathic effects of the virus itself.
Consistent with our previous experiments showing that
the CCR2-deficient mice have enhanced early accumu-
lation and delayed clearance of neutrophils in response
to intraperitoneal thioglycollate injection,32 neutrophils
persisted in the influenza virus infected lung of the
CCR2/ mice. The delay in macrophage response
resulting in reduced phagocytosis is at least partly
responsible for the prolonged presence of neutrophils
in lungs of the CCR2/ mice. It is also likely that the
neutrophilic persistence seen at later time points in our
flu experiments are because of the consistent migra-
tion of new neutrophils into the lung. No evidence of
defective apoptosis of neutrophils has been demon-
strated in CCR2/ mice.
Our data with the CCR2-deficient mice further show
that the delay in the macrophage response leads to a
subsequent delay in CTL development and/or migration
to the infected lungs. This delay in T cell response is likely
responsible for the increased viral load 5 days postinfec-
tion. It has been shown that CCR2 expression is inducible
on T lymphocytes,47–48 and T lymphocytes can respond
to MCP-1 at high levels in vitro.49 Thus, the apparent lack
of T cell involvement in the lungs of CCR2/ mice could,
at least in part, be directly related to the absence of
CCR2 from circulating T cells. However, this is unlikely to
account for the majority of the delays in leukocyte accu-
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mulation in the CCR2/ mice because the delays are
seen at very early time points, when monocytes, not T
cells, are widely regarded as the primary responders to
induced MCP-1 expression in vivo. It is also important to
note that whereas the CCR2 deficiency confers patholog-
ical protection at early time points, CCR2-deficient mice
eventually mount a pulmonary mononuclear response
that is sufficient to allow for tissue recovery with no sig-
nificant rise in mortality. Obviously, there is some com-
pensatory mechanism that might involve other chemo-
kines and chemokine receptors, such as MIP-1 or IP-10.
We observed increased expression of IP-10 (Figure 6A),
and IP-10 expression is markedly increased after influ-
enza A virus infection of cultured human monocytes.25
Like MCP-1, IP-10 promotes chemotaxis of monocytes
and T lymphocytes,50 but it functions through CXCR3.4
Another intriguing possibility is the binding of MCP-1 to
receptors other than CCR2. High levels of local MCP-1,
resulting from the increased MCP-1 mRNA produced
after infection, may help facilitate the binding of MCP-1 to
alternative chemokine receptors.
Mice deficient in both CCR2 and MIP-1 show the best
survival and the highest viral titers among all groups used
in this study. This is consistent with the idea that MCP-1
and MIP-1 make distinct and additive contributions to
the pulmonary inflammation induced by influenza virus
infections. Absence of CCR2 clearly blocks the majority
of the early pulmonary macrophage accumulation,
whereas others have shown that MIP-1 is the major
regulator of T-cell trafficking into lymph nodes and spe-
cific tissues in response to a variety of antigenic stimuli,
including influenza A virus.22,51–52
Altogether, our data demonstrate that the cell-medi-
ated mechanism normally used in influenza-infected host
tissues includes initial macrophage activation and re-
cruitment via MCP-1 expression, followed by a quick and
precise CTL attack against the influenza A virus. We
show that elimination of either CCR5 or CCR2 signifi-
cantly affects the course immune mechanisms as well as
the clinical outcome, although in profoundly different
ways. Altering the homing or phenotypic characteristics
of the alveolar macrophages can cause an overwhelm-
ing, sometimes fatal early leukocyte response, as in the
CCR5/ mice. In contrast, reducing the migratory capa-
bility of the peripheral blood monocytes/macrophages
confers protection from severe influenza-induced tissue
damage at early time points, as seen in the CCR2/
mice. Although there is clear overlap in CC chemokine
receptor expression patterns in this case (and many oth-
ers), the availability of chemokines and chemokine re-
ceptors in vivo has been repeatedly shown to be a highly
specific, finely controlled, and tightly regulated process,
making therapeutic disruption a distinct possibility. Our
data indicate that an efficacious therapeutic agent might
be one that targets the beginning stages of the early
leukocyte inflammatory cascade, or more particularly,
one that can specifically alter normal macrophage func-
tion. However, decreasing macrophage function could
cause an increased susceptibility to secondary bacterial
infections.53 This possibility must be carefully considered
during future investigations into the pathogenesis of the
influenza A virus.
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